What it is
An extract of the leaf of Ginkgo biloba, a tree species that has been around for an extraordinarily long time — a fact mentioned on every ginkgo product and relevant to none of them. What matters is the standardised extract: typically specified for flavone glycosides and terpene lactones, which is what the research used and what a label should state.
The proposed mechanism
Circulation through the smallest vessels. The flavone glycosides and terpene lactones have been studied for their effect on flow through capillaries, and that is the account on which the whole category rests.
It is a plausible mechanism and it is worth saying that plausible is not the same as demonstrated at the level of outcomes people care about.
The trial that found something
Kaschel, 2011. 188 healthy adults aged 45 to 56 took a standardised 240 mg extract for six weeks. The measured outcome was recall of appointments they had agreed to keep — and on that measure the ginkgo group outperformed placebo.
That is the clearest controlled memory result attached to any ingredient in this category, and it is worth taking seriously. It is also one task, in one study, in 188 middle-aged people with no diagnosis.
What the same trial did not find
No advantage on recognition memory. Recall improved; recognition did not. Any page citing this study without that sentence is quoting half of it.
The trials that found nothing
The Ginkgo Evaluation of Memory study, published by DeKosky in JAMA in 2008, followed more than three thousand older adults for six years. It was testing whether ginkgo reduced the incidence of dementia. It did not.
Snitz, the following year, looked at broader cognitive decline in the same cohort and found no slowing there either.
These are the largest and longest trials in the field and their result is negative. Nothing about the shorter, narrower positive finding erases that, and a page that cites one while omitting the other is managing your impression rather than informing you.
How to read the two together
The defensible reading is narrow: over six weeks, in healthy middle-aged adults, one specific kind of recall improved. Over six years, in older adults, the incidence of disease did not change.
Those statements are compatible. A modest short-term effect on a specific task is not the same claim as prevention of a neurodegenerative disease, and ginkgo has been tested for both.
The safety point that actually matters
Ginkgo has been associated with increased bleeding risk. That makes it a genuine concern alongside warfarin, apixaban, rivaroxaban, clopidogrel and daily aspirin, and the standard advice is to stop two weeks before surgery or a dental extraction.
It is generally advised against for people with seizure disorders. Interactions with SSRIs, MAOIs and lithium have been described. None of this makes it dangerous for most people; all of it makes a pharmacist conversation worthwhile if you take anything regularly. The safety page covers it in more detail.
Ginkgo in combination
Ginkgo rarely appears alone. A ginkgo biloba and turmeric supplement pairs a six-week circulation story with an eighteen-month antioxidant one. A ginkgo biloba and green tea supplement pairs it with the only same-day evidence in the category. A ginkgo biloba turmeric green tea supplement does both at once.
The reasonable case for a ginkgo biloba turmeric memory supplement is that the two ingredients are doing unrelated things on unrelated clocks, so combining them covers more ground than doubling either. The unreasonable case is implying that three ingredients produce three times the effect. They do not, and nothing published suggests they interact to produce more than the sum of their modest parts.
What to look for on a label
- A stated milligram amount, not a blend total.
- Leaf extract, standardised, rather than unspecified ginkgo powder.
- A seller willing to mention the GEM result rather than only the 2011 one.
In VapoCept, ginkgo biloba leaf extract is listed separately with its own amount on the supplement facts panel.